Castle Biosciences
CSTL
188 hedge funds and large institutions have $1.42B invested in Castle Biosciences in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 80 increasing their positions, 56 reducing their positions, and 14 closing their positions.
186% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $767K
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
43% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 56
3% more funds holding
Funds holding: 182 → 188 (+6)
2.4% more ownership
Funds ownership: 83.03% → 85.43% (+2.4%)
7% less capital invested
Capital invested by funds: $1.52B → $1.42B (-$99.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$28.4M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$12.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12M |
| 4 |
CA
CastleArk Alternatives
Chicago,
Illinois
|
+$10.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$32.9M |
| 2 |
RI
RTW Investments
New York
|
-$14.1M |
| 3 |
Goldman Sachs
New York
|
-$7.54M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.5M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
-$5.05M |
CSTL Hedge Fund Activity: Q3 2021 in Review
188 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2021, worth a combined $1.42B — down 6.5% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CSTL positions and 14 closed out — a net gain of 6 holders — while 80 added to existing stakes and 56 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $28.4M. The largest seller was ARK Investment Management, cutting an estimated $32.9M.
- 188 institutional investors held Castle Biosciences (CSTL) as of Q3 2021, up from 182 in Q2 2021.
- Funds reported $1.42B of Castle Biosciences stock for Q3 2021, down 6.5% quarter-over-quarter.
- 20 funds opened new Castle Biosciences positions in Q3 2021 and 14 closed out, a net change of +6 holders.
- The largest Castle Biosciences buyer in Q3 2021 was Millennium Management, an estimated $28.4M added.
- The largest Castle Biosciences seller in Q3 2021 was ARK Investment Management, an estimated $32.9M sold.
Based on aggregated 13F filings for Q3 2021.